A Simple-to-Use Nomogram for Predicting the Survival of Early Hepatocellular Carcinoma Patients

Objective: This study aimed to develop and validate a simple-to-use nomogram for early hepatocellular carcinoma (HCC) patients undergoing a preoperative consultation and doctors conducting a postoperative evaluation. Methods: A total of 2,225 HCC patients confirmed with stage I or II were selected from the Surveillance, Epidemiology, and End Results database between January 2010 and December 2015. The patients were randomly divided into two groups: a training group (n = 1,557) and a validation group (n= 668). Univariate and multivariate hazards regression analyses were used to identify independent prognostic factors. The Akaike information criterion (AIC) was used to select variables for the nomogram. The performance of the nomogram was validated concerning its ability of discrimination and calibration and its clinical utility. Results: Age, alpha-fetoprotein (AFP), race, the degree of differentiation, and therapy method were significantly associated with the prognosis of early HCC patients. Based on the AIC results, five variables (age, race, AFP, degree of differentiation, and therapy method) were incorporated into the nomogram. The concordance indexes of the simple nomogram in the training and validation groups were 0.707 (95% CI: 0.683–0.731) and 0.733 (95% CI: 0.699–0.767), respectively. The areas under the receiver operating characteristic (ROC) curve of the nomogram in the training and validation groups were 0.744 and 0.764, respectively, for predicting 3-year survival, and 0.786 and 0.794, respectively, for predicting 5-year survival. Calibration plots showed good consistency between the predictions of the nomogram and the actual observations in both the training and validation groups. Decision curve analysis (DCA) showed that the simple nomogram was clinically useful, and the overall survival significantly differed between lowand high-risk groups divided by the median score of the nomogram in the training group (P < 0.001). Conclusion: A simple-to-use nomogram based on a large population-based study is developed and validated, which is a conventional tool for doctors to facilitate the individual consultation of preoperative patients and the postoperative personalized evaluation.

[1]  L. Kulik,et al.  Hepatocellular carcinoma , 2022, Nature Reviews Disease Primers.

[2]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[3]  S. J. Henley,et al.  Uterine Cancer Incidence and Mortality — United States, 1999–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[4]  Jason D. Wright,et al.  Survival after Minimally Invasive Radical Hysterectomy for Early‐Stage Cervical Cancer , 2018, The New England journal of medicine.

[5]  Sheng-ping Li,et al.  Nomogram to Predict Cancer-Specific Survival in Patients with Pancreatic Acinar Cell Carcinoma: A Competing Risk Analysis , 2018, Journal of Cancer.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  Sheng-ping Li,et al.  Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis , 2018, Journal of Cancer.

[8]  K. Chayama,et al.  Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity‐matched analysis in a single institution , 2018, Surgery.

[9]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[10]  J. Saltzman,et al.  Thirty-Day Readmission Among Patients With Non-Variceal Upper Gastrointestinal Hemorrhage and Effects on Outcomes. , 2018, Gastroenterology.

[11]  Tianyuan Xu,et al.  Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder , 2018, Journal of Cancer.

[12]  Y. Tao,et al.  Thermal ablation versus surgical resection for localized hepatocellular carcinoma: a population study using the SEER database. , 2018, Future oncology.

[13]  H. Wen,et al.  Survival prediction model for postoperative hepatocellular carcinoma patients , 2017, Medicine.

[14]  A. Mehrabi,et al.  Early stage hepatocellular carcinoma in the elderly: A SEER database analysis. , 2017, Journal of geriatric oncology.

[15]  elliot k fishman,et al.  Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma. , 2017, The Journal of surgical research.

[16]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[17]  Ying Feng,et al.  Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma , 2017, BMC Cancer.

[18]  Yanqi Huang,et al.  Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Benjamin R Saville,et al.  Decision curve analysis. , 2015, JAMA.

[20]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[21]  Ramesh C. Gupta,et al.  Competing Risk Analysis , 2014 .

[22]  M. Choti,et al.  Surgical Therapy for Early Hepatocellular Carcinoma in the Modern Era: A 10-Year SEER-Medicare Analysis , 2013, Annals of surgery.

[23]  R. Santambrogio,et al.  External validation of a simplified BCLC staging system for early hepatocellular carcinoma. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  F. Mach,et al.  Alpha-fetoprotein: a controversial prognostic biomarker for small hepatocellular carcinoma. , 2013 .

[25]  M. Zoli,et al.  Alpha‐fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis , 2012, Hepatology.

[26]  S. Ahn,et al.  Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. , 2011, European journal of cancer.

[27]  Roman Rouzier,et al.  Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Choti,et al.  Comparative performances of staging systems for early hepatocellular carcinoma. , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[29]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[30]  M. Choti,et al.  Predictors of Survival After Resection of Early Hepatocellular Carcinoma , 2009, Annals of surgery.

[31]  M. Makuuchi,et al.  Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. , 2009, Journal of hepatology.

[32]  K. Takeda,et al.  Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. , 2008, Radiology.

[33]  A. Elola-Olaso,et al.  Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors. , 2007, Transplantation proceedings.

[34]  T. Asahara,et al.  Clinicopathologic features of poorly differentiated hepatocellular carcinoma , 2007, Journal of surgical oncology.

[35]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  T. Nagayasu,et al.  Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[38]  M. Kudo,et al.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) , 2003, Journal of Gastroenterology.

[39]  L. Qin,et al.  The prognostic significance of clinical and pathological features in hepatocellular carcinoma. , 2002, World journal of gastroenterology.

[40]  K. Leung,et al.  Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system , 2002, Cancer.

[41]  H. El‐Serag,et al.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States , 2001, Hepatology.

[42]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[43]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[44]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[45]  G. D’Amico,et al.  Hepatocellular carcinoma , 1991, Digestive Diseases and Sciences.

[46]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[47]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[48]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[49]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[50]  H. El‐Serag,et al.  Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study , 2006 .

[51]  C. Gonçalves,et al.  [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.

[52]  Douglas G. Altman,et al.  Explanation and Elaboration , 2022 .